WO2019022235A9 - 円形脱毛症の治療剤又は予防剤 - Google Patents

円形脱毛症の治療剤又は予防剤 Download PDF

Info

Publication number
WO2019022235A9
WO2019022235A9 PCT/JP2018/028277 JP2018028277W WO2019022235A9 WO 2019022235 A9 WO2019022235 A9 WO 2019022235A9 JP 2018028277 W JP2018028277 W JP 2018028277W WO 2019022235 A9 WO2019022235 A9 WO 2019022235A9
Authority
WO
WIPO (PCT)
Prior art keywords
agent
alopecia areata
therapeutic agent
prophylactic
prophylactic agent
Prior art date
Application number
PCT/JP2018/028277
Other languages
English (en)
French (fr)
Other versions
WO2019022235A1 (ja
Inventor
理恵 佐々木
新之助 林
マーシャル バレット
慎也 横坂
和也 大角
拓実 青木
目黒　裕之
戒能　美枝
こずえ 高垣
雄大 高橋
Original Assignee
東レ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東レ株式会社 filed Critical 東レ株式会社
Priority to JP2018543738A priority Critical patent/JPWO2019022235A1/ja
Priority to US16/633,956 priority patent/US10881649B2/en
Priority to EP18837535.6A priority patent/EP3659602A4/en
Priority to CN201880049741.5A priority patent/CN110913859A/zh
Priority to CA3071235A priority patent/CA3071235A1/en
Priority to KR1020197034497A priority patent/KR20200033224A/ko
Priority to AU2018307888A priority patent/AU2018307888A1/en
Priority to RU2020108223A priority patent/RU2772507C2/ru
Priority to BR112020001588-1A priority patent/BR112020001588A2/pt
Publication of WO2019022235A1 publication Critical patent/WO2019022235A1/ja
Publication of WO2019022235A9 publication Critical patent/WO2019022235A9/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

本発明は、ＲＯＲγアンタゴニスト活性を有する、円形脱毛症の治療剤又は予防剤を提供することを目的とし、この目的を達成するために、下記化合物に代表される環状アミン誘導体又はその薬理学的に許容される塩を有効成分として含有する、円形脱毛症の治療剤又は予防剤を提供する。
PCT/JP2018/028277 2017-07-27 2018-07-27 円形脱毛症の治療剤又は予防剤 WO2019022235A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2018543738A JPWO2019022235A1 (ja) 2017-07-27 2018-07-27 円形脱毛症の治療剤又は予防剤
US16/633,956 US10881649B2 (en) 2017-07-27 2018-07-27 Therapeutic agent or preventive agent for alopecia areata
EP18837535.6A EP3659602A4 (en) 2017-07-27 2018-07-27 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR ALOPECIA AREATA
CN201880049741.5A CN110913859A (zh) 2017-07-27 2018-07-27 圆形脱毛症的治疗剂或预防剂
CA3071235A CA3071235A1 (en) 2017-07-27 2018-07-27 Therapeutic agent or preventive agent for alopecia areata
KR1020197034497A KR20200033224A (ko) 2017-07-27 2018-07-27 원형 탈모증의 치료제 또는 예방제
AU2018307888A AU2018307888A1 (en) 2017-07-27 2018-07-27 Therapeutic agent or prophylactic agent for alopecia areata
RU2020108223A RU2772507C2 (ru) 2017-07-27 2018-07-27 Терапевтическое средство или профилактическое средство против гнездной алопеции
BR112020001588-1A BR112020001588A2 (pt) 2017-07-27 2018-07-27 agente terapêutico ou um agente preventivo para alopecia areata

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-145442 2017-07-27
JP2017145442 2017-07-27

Publications (2)

Publication Number Publication Date
WO2019022235A1 WO2019022235A1 (ja) 2019-01-31
WO2019022235A9 true WO2019022235A9 (ja) 2019-04-18

Family

ID=65039597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/028277 WO2019022235A1 (ja) 2017-07-27 2018-07-27 円形脱毛症の治療剤又は予防剤

Country Status (9)

Country Link
US (1) US10881649B2 (ja)
EP (1) EP3659602A4 (ja)
JP (1) JPWO2019022235A1 (ja)
KR (1) KR20200033224A (ja)
CN (1) CN110913859A (ja)
AU (1) AU2018307888A1 (ja)
BR (1) BR112020001588A2 (ja)
CA (1) CA3071235A1 (ja)
WO (1) WO2019022235A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022064291A (ja) 2020-10-13 2022-04-25 信越化学工業株式会社 生体電極組成物、生体電極、生体電極の製造方法、高分子化合物及び複合体
KR20230076422A (ko) 2021-11-24 2023-05-31 경희대학교 산학협력단 데커신을 포함하는 탈모 치료 또는 예방용 약학조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2548618A3 (en) 2008-07-15 2013-02-27 Novartis AG Heteroaryl derivatives as DGAT1 inhibitors
WO2010096371A2 (en) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the cb2 receptor
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
EP2638014B1 (en) 2010-11-08 2017-01-04 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases
AR086156A1 (es) 2011-04-28 2013-11-20 Japan Tobacco Inc Compuesto de amida y su uso medicinal
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
GB201207406D0 (en) * 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
MX2014014614A (es) 2012-05-31 2015-02-12 Phenex Pharmaceuticals Ag Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huerfano ror [gamma).
CN106132931B (zh) * 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
CN106061947B (zh) 2014-01-06 2019-12-03 百时美施贵宝公司 环己基砜RORγ调节剂
US9663515B2 (en) * 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) * 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TWI691486B (zh) * 2016-01-29 2020-04-21 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途

Also Published As

Publication number Publication date
KR20200033224A (ko) 2020-03-27
EP3659602A4 (en) 2021-06-09
WO2019022235A1 (ja) 2019-01-31
BR112020001588A2 (pt) 2020-07-21
RU2020108223A (ru) 2021-08-27
US20200215046A1 (en) 2020-07-09
AU2018307888A1 (en) 2020-01-30
US10881649B2 (en) 2021-01-05
RU2020108223A3 (ja) 2021-11-08
EP3659602A1 (en) 2020-06-03
CA3071235A1 (en) 2019-01-31
CN110913859A (zh) 2020-03-24
JPWO2019022235A1 (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
PH12016501813B1 (en) 1,3-benzodioxole derivative
MX2023001876A (es) Derivados de rapamicina.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
MX2016014946A (es) Derivados de carboxamida.
PH12019550154A1 (en) Azetidine derivative
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
MX360699B (es) Derivados de espiro [2.4] heptano puenteado substituidos por piperazina, utilizados como agonistas del receptor alx.
WO2019022235A9 (ja) 円形脱毛症の治療剤又は予防剤
MX2015017541A (es) Derivados de espiro [2.4] heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx.
MX2020008929A (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MY201356A (en) Therapeutic or prophylactic agent for peripheral neuropathies
MX2018015990A (es) Compuestos terapeuticos.
MX2016009932A (es) Agente terapeutico o profilactico para esclerosis multiple.
PH12019501027A1 (en) Therapeutic drug or prophylactic drug for diabetic nephropathy
AU2019214044A1 (en) Cyclic amine derivative and pharmaceutical use thereof
PH12016502247A1 (en) Carboxamide derivatives

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018543738

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18837535

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3071235

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018307888

Country of ref document: AU

Date of ref document: 20180727

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020001588

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018837535

Country of ref document: EP

Effective date: 20200227

ENP Entry into the national phase

Ref document number: 112020001588

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200124